ClinicalTrials.gg
RecruitingNCT07580638Updated Nov 5, 2026

Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes

An observational study in T2DM (Type 2 Diabetes Mellitus), sponsored by Chipscreen Biosciences, Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Chipscreen Biosciences, Ltd. · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 5, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,550
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
34th of 143
3,550 · median 556
Started
2026
with 88 others
Observational
143 of 913
56 open now
Primary completion
2028-01
later than 170 of 228 live
Registered
831st of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 34th largest by planned enrollment of the 143 observational ones that give a count, is one of 89 that started in 2026, is one of 143 observational ones, reaches primary completion later than 170 of the 228 other live ones, and was the 831st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

199 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with Type 2 Diabetes Mellitus (T2DM) . The main questions it aims to answer are:

What is the real-world effectiveness of Chiglitazar, when added to an SGLT-2 inhibitor, on glycemic control? What are the effects of this combination therapy on cardiovascular, renal, and hepatic outcomes? What is the overall safety of this treatment regimen?

This is a non-interventional study. Participants will be prescribed Chiglitazar or other oral antidiabetic drugs by their treating physician as part of their routine clinical care. For the purpose of this registry study, data will be collected from their regular medical follow-ups. Participants will:

Attend regular follow-up visits as part of their standard diabetes care. Have data collected from their routine clinical assessments.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

T2DM patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years, inclusive.
  • Diagnosis of Type 2 Diabetes Mellitus (T2DM) .
  • Receiving stable-dose SGLT-2 inhibitor monotherapy or in combination with one other oral antidiabetic drug for at least one month prior to screening, but with inadequate glycemic control, defined as ≥ 7.5%.
  • Must be willing to participate and have provided written .

Exclusion criteria

Exclusion Criteria:

  • Current or routine use of insulin therapy.
  • Use of three or more antidiabetic drugs within one month prior to screening.
  • Current treatment with a thiazolidinedione (TZD) or a GLP-1 receptor agonist (GLP-1 RA).
  • Prior treatment with Chiglitazar Sodium.
  • Presence of life-threatening comorbidities, severe edema, or severe hepatic impairment ( Class C).
  • Laboratory findings meeting any of the following criteria: a) (AST) or Alanine aminotransferase (ALT) > 5 times the (ULN); b) Estimated (eGFR) \< 30 mL/min/1.73 m².
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,550 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chiglitazar Cohort (Exposure Group)

    Participants with T2DM on a background SGLT-2 inhibitor-based therapy who are newly prescribed Chiglitazar by their treating physician. This cohort includes patients on dual therapy (SGLT-2i + Chiglitazar) or triple therapy (SGLT-2i + Chiglitazar + another oral antidiabetic drug).

    Drug: SGLT-2 inhibitor and Chiglitazar

  • Comparator Cohort (Control Group)

    Participants with T2DM on a background SGLT-2 inhibitor-based therapy who are prescribed oral antidiabetic drugs (other than Chiglitazar)

    Drug: SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs)

Interventions

  • DrugSGLT-2 inhibitor and Chiglitazar

    Drug pages: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ChiglitazarStudies of ChiglitazarChiglitazar pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prescribed as an add-on therapy to an SGLT-2 inhibitor-based regimen according to the physician's clinical judgment and routine practice

  • DrugSGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs)

    Any oral antidiabetic drug (other than Chiglitazar) prescribed by the treating physician as an add-on therapy to an SGLT-2 inhibitor-based regimen.

06

What researchers measure

Primary outcomes

  1. Glycated Hemoglobin (HbA1c)

    Change From Baseline in Glycated Hemoglobin (HbA1c) at 6 Months

    Time frame: Baseline, 6 Months

Secondary outcomes

  1. N-terminal pro-B-type natriuretic peptide

    To assess the change from baseline in N-terminal pro-B-type natriuretic peptide

    Time frame: Baseline, 6 Months, 12 Months

  2. High-sensitivity C-reactive Protein

    To assess the change from baseline in High-sensitivity C-reactive Protein

    Time frame: Baseline, 6 Months, 12 Months

  3. Liver Chemistries: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TBIL), and Gamma-Glutamyl Transferase (GGT).

    To assess the change from baseline in Liver Function Test Markers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TBIL), and Gamma-Glutamyl Transferase (GGT).

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  4. Renal Function Markers: estimated Glomerular Filtration Rate, Urine Albumin-to-Creatinine Ratio, Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and Cystatin C

    To assess the change from baseline in markers for chronic kidney disease, including estimated Glomerular Filtration Rate, Urine Albumin-to-Creatinine Ratio, Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and Cystatin C.

    Time frame: Baseline, 6 Months, 12 Months.

  5. Resolution Rate of Metabolic Syndrome

    Time frame: 6 Months, 12 Months.

  6. Proportion of Patients Achieving Glycemic Control Targets

    To assess the percentage of patients reaching predefined Glycated Hemoglobin targets of \<6.5%, \<7.0%, and \<7.5%.

    Time frame: 3 Months, 6 Months, 9 Months, 12 Months.

  7. Glycated Hemoglobin

    To assess the change from baseline in Glycated Hemoglobin (HbA1c).

    Time frame: Baseline, 3 Months, 9 Months, 12 Months.

  8. Fasting Blood Glucose

    To assess the change from baseline in fasting blood glucose.

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  9. Patient-Reported Quality of Life (DSQL) score

    To measure the change in patient-reported quality of life using the Diabetes-Specific Quality of Life (DSQL) score.

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  10. Incidence of Adverse Events

    Time frame: Up to 12 months

  11. Medication Costs

    To assess the medication costs associated with Type 2 Diabetes.

    Time frame: Up to 12 months

  12. Incidence of Major Adverse Cardiovascular Events (MACE)

    To assess the number of participants experiencing one or more components of MACE (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke).

    Time frame: Up to 12 months.

  13. non-invasive scores for liver steatosis and fibrosis: Fibrosis-4 Index

    Time frame: Baseline, 6 Months,12 Months.

  14. blood pressure (systolic and diastolic)

    To assess the change from baseline in blood pressure (systolic and diastolic).

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  15. body weight

    To assess the change from baseline in body weight.

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  16. waist circumference

    To assess the change from baseline in waist circumference.

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  17. Body Mass Index

    To assess the change from baseline in Body Mass Index.

    Time frame: Baseline, 3 Months, 6 Months, 9 Months, 12 Months.

  18. Triglycerides(TG)

    To assess the change from baseline in Triglycerides(TG)

    Time frame: Baseline, 6 Months, 12 Months

  19. Total Cholesterol (TC)

    To assess the change from baseline in Total Cholesterol (TC)

    Time frame: Baseline, 6 Months, 12 Months

  20. Low-Density Lipoprotein Cholesterol (LDL-C)

    To assess the change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline, 6 Months, 12 Months

  21. High-Density Lipoprotein Cholesterol (HDL-C)

    To assess the change from baseline in High-Density Lipoprotein Cholesterol (HDL-C)

    Time frame: Baseline, 6 Months, 12 Months

  22. Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

    To assess the change from baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

    Time frame: Baseline, 6 Months, 12 Months

  23. Free Fatty Acids (FFA)

    To assess the change from baseline in Free Fatty Acids (FFA)

    Time frame: Baseline, 6 Months, 12 Months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 16 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 12, 2026
StartActual
Sep 4, 2026was Jul 2026
Primary completionEst.
Jan 18, 2028
CompletionEst.
Jul 18, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Beijing Hospital · Beijing, China
  • West China Hospital of Sichuan University · Chengdu, China
Nov 5, 2026
Start date
Jul 18, 2026→Sep 4, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Beijing Hospital · Beijing, China
    • West China Hospital of Sichuan University · Chengdu, China
    Start date Jul 18, 2026→Sep 4, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07580638
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Sep 4, 2026
Primary completion
Jan 18, 2028 (estimated)
Completion
Jul 18, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Wang
Contact
xinhwang@chipscreen.com
+86 0755-36993550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion